Targeted anti-apoptosis activity for ovarian protection against chemotherapy-induced ovarian gonadotoxicity

Reproductive BioMedicine Online

Volumn 29, Issue 5, 2014, Pages 612-620

  Tan, Shun Jen ^a,b   Lee, Li Jen ^c   Tzeng, Chii Ruey ^a,d   Wang, Chia Woei ^a,d   Hsu, Ming I ^e   Chen, Chi Huang ^a,d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

anti apoptotic therapy; anti M llerian hormone; caspase 3; fertility preservation; gonadotoxicity; sphingosine 1 phosphate

Indexed keywords

BUSULFAN; CASPASE 3; GROWTH DIFFERENTIATION FACTOR 9; MESSENGER RNA; MUELLERIAN INHIBITING FACTOR; PROTECTIVE AGENT; SPHINGOSINE 1 PHOSPHATE; ANTINEOPLASTIC AGENT; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DESTRUCTION; CHEMOTHERAPY INDUCED REPRODUCTIVE TOXICITY; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GONAD FUNCTION; GRANULOSA CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LOW DRUG DOSE; MOUSE; NONHUMAN; OOCYTE; OVARIAN RESERVE; OVARY FOLLICLE; OVARY FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCTIVE TOXICITY; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DNA DAMAGE; DRUG EFFECTS; FERTILITY; METABOLISM; OVARY;

ANIMALS; ANTI-MULLERIAN HORMONE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BUSULFAN; CASPASE 3; DNA DAMAGE; FEMALE; FERTILITY; GRANULOSA CELLS; IMMUNOHISTOCHEMISTRY; LYSOPHOSPHOLIPIDS; MICE; OVARIAN FOLLICLE; OVARY; RNA, MESSENGER; SPHINGOSINE;

EID: 84908395184     PISSN: 14726483     EISSN: 14726491     Source Type: Journal    
DOI: 10.1016/j.rbmo.2014.07.014     Document Type: Article

References (64)

1. Abir R., Ben-Haroush A., Felz C., Okon E., Raanani H., Orvieto R., Nitke S., and Fisch B. Selection of patients before and after anticancer treatment for ovarian cryopreservation Hum. Reprod 23 2008 869 877
2. Anderson R.A., and Cameron D.A. Pretreatment serum anti-Mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer J. Clin. Endocrinol. Metab 96 2011 1336 1343
3. Anderson R.A., Themmen A.P., Al-Qahtani A., Groome N.P., and Cameron D.A. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer Hum. Reprod 21 2006 2583 2592
4. Beck-Fruchter R., Weiss A., and Shalev E. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data Hum. Reprod. Update 14 2008 553 561
5. Blumenfeld Z., Katz G., and Evron A. 'An ounce of prevention is worth a pound of cure': the case for and against GnRH-agonist for fertility preservation Ann. Oncol 2014 10.1093/annonc/mdu036 Epub ahead of print
6. Broekmans F.J., Kwee J., Hendriks D.J., Mol B.W., and Lambalk C.B. A systemic review of tests predicting ovarian reserve and IVF outcome Hum. Reprod. Update 12 2006 685 718
7. Chen H., Li J., Cui T., and Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women Cochrane Database Syst. Rev 11 2011 CD008018
8. Cuvillier O., Pirianov G., Kleuser B., Vanek P.G., Coso O.A., Gutkind S., and Spiegel S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate Nature 381 1996 800 803
9. Del Mastro L., Ceppi M., Poggio F., Bighin C., Peccatori F., Demeestere I., Levaggi A., Giraudi S., Lambertini M., D'Alonzo A., Canavese G., Pronzato P., and Bruzzi P. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials Cancer Treat. Rev 40 2014 675 683
10. Domingues T.S., Rocha A.M., and Serafini P.C. Tests for ovarian reserve: reliability and utility Curr. Opin. Obstet. Gynecol 22 2010 271 276
11. Dong J., Albertini D.F., Nishimori K., Kumar T.R., Lu N., and Matzuk M.M. Growth differentiation factor-9 is required during early ovarian folliculogenesis Nature 383 1996 531 535
12. Fenwick M.A., and Hurst P.R. Immunohistochemical localization of active caspase-3 in the mouse ovary: growth and atresia of small follicles Reproduction 124 2002 659 665
13. Fitzpatrick S.L., Sindoni D.M., Shughrue P.J., Lane M.V., Merchenthaler I.J., and Frail D.E. Expression of growth differentiation factor-9 messenger ribonucleic acid in ovarian and nonovarian rodent and human tissues Endocrinology 139 1998 2571 2578
14. Glamoclija V., Vilovic K., Saraga-Babic M., Baranovic A., and Sapunar D. Apoptosis and active caspase-3 expression in human granulosa cells Fertil. Steril 83 2005 426 431
15. Gonfloni S., Tella L.D., Caldarola S., Cannata S.M., Klinger F.G., Di Bartolomeo C., Mattei M., Candi E., De Felici M., Melino G., and Cesareni G. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death Nat. Med 15 2009 1179 1185
16. Hadjiloucas I., Gilmore A.P., Bundred N.J., and Streuli C.H. Assessment of apoptosis in human breast tissue using an antibody against the active form of caspase 3: relation to tumour histopathological characteristics Br. J. Cancer 85 2001 1522 1526
17. Hancke K., Strauch O., Kissel C., Göbel H., Schäfer W., and Denschlag D. Sphingosine 1-phosphate protects ovaries from chemotherapy-induced damage in vivo Fertil. Steril 87 2007 172 177
18. Hansen K.R., Hodnett G.M., Knowlton N., and Craig L.B. Correlation of ovarian reserve tests with histologically determined primordial follicle number Fertil. Steril 95 2011 170 175
19. Hayashi M., McGee E.A., Min G., Klein C., Rose U.M., van Duin M., and Hsueh A.J. Recombinant growth differentiation factor-9 (GDF9) enhances growth and differentiation of cultured early ovarian follicles Endocrinology 140 1999 1236 1244
20. Hayun M., Naor Y., Weil M., Albeck M., Peled A., Don J., Haran-Ghera N., and Sredni B. The immunomodulator AS101 induces growth arrest and apoptosis in multiple myeloma: association with the Akt/survivin pathway Biochem. Pharmacol 72 2006 1423 1431
21. Hreinsson J.G., Scott J.E., Rasmussen C., Swahn M.L., Hsueh A.J., and Hovatta O. Growth differentiation factor-9 promotes the growth, development, and survival of human ovarian follicles in organ culture J. Clin. Endocrinol. Metab 87 2002 316 321
22. Hurst P.R., Mora J.M., and Fenwick M.A. Caspase-3, TUNEL and ultrastructural studies of small follicles in adult human ovarian biopsies Hum. Reprod 21 2006 1974 1980
23. Kalich-Philosoph L., Roness H., Carmely A., Fishel-Bartal M., Ligumsky H., Paglin S., Wolf I., Kanety H., Sredni B., and Meirow D. Cyclophosphamide triggers follicle activation and "burnout"; AS101 prevents follicle loss and preserves fertility Sci. Transl. Med 5 2013 185ra62
24. Kedem A., Fisch B., Garor R., Ben-Zaken A., Gizunterman T., Felz C., Ben-Haroush A., Kravarusic D., and Abir R. Growth differentiating factor 9 (GDF9) and bone morphogenetic protein 15 both activate development of human primordial follicles in vitro, with seemingly more beneficial effects of GDF9 J. Clin. Endocrinol. Metab 96 2011 E1246 E1254
25. Kerr J.B., Hutt K.J., Cook M., Speed T.P., Strasser A., Findlay J.K., and Scott C.L. Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib Nat. Med 18 2012 1170 1172
26. Kevenaar M.E., Meerasahib M.F., Kramer P., van de Lang-Born B.M., de Jong F.H., Groome N.P., Themmen A.P., and Visser J.A. Serum anti-Mullerian hormone levels reflect the size of the primordial follicle pool in mice Endocrinology 147 2006 3228 3234
27. La Marca A., Stabile G., Artenisio A.C., and Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle Hum. Reprod 21 2006 3103 3107
28. Larsen E.C., Müller J., Schmiegelow K., Rechnitzer C., and Andersen A.N. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer J. Clin. Endocrinol. Metab 88 2003 5307 5314
29. Larsen E.C., Müller J., Rechnitzer C., Schmiegelow K., and Andersen A.N. Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH <10 IU/l Hum. Reprod 18 2003 417 422
30. Lass A. Assessment of ovarian reserve: is there still a role for ovarian biopsy in the light of new data? Hum. Reprod 19 2004 467 469
31. Lie Fong S., Laven J.S., Hakvoort-Cammel F.G., Schipper I., Visser J.A., Themmen A.P., de Jong F.H., and van den Heuvel-Eibrink M.M. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone Hum. Reprod 24 2009 982 990
32. Lim E.J., and Choi Y. Transcription factors in the maintenance and survival of primordial follicles Clin. Exp. Reprod. Med 39 2012 127 131
33. Matzuk M.M., Burns K.H., Viveiros M.M., and Eppig J.J. Intercellular communication in the mammalian ovary: oocytes carry the conversation Science 296 2002 2178 2180
34. McGrath S.A., Esquela A.F., and Lee S.J. Oocyte-specific expression of growth/differentiation factor-9 Mol. Endocrinol 9 1995 131 136
35. McNatty K.P., Juengel J.L., Reader K.L., Lun S., Myllymaa S., Lawrence S.B., Western A., Meerasahib M.F., Mottershead D.G., Groome N.P., Ritvos O., and Laitinen M.P. Bone morphogenetic protein 15 and growth differentiation factor 9 co-operate to regulate granulosa cell function Reproduction 129 2005 473 480
36. Meirow D., Lewis H., Nugent D., and Epstein M. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool Hum. Reprod 14 1999 1903 1907
37. Meirow D., Dor J., Kaufman B., Shrim A., Rabinovici J., Schiff E., Raanani H., Levron J., and Fridman E. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury Hum. Reprod 22 2007 1626 1633
38. Meirow D., Philosof-Kalich L., Carmely A., Bartal M., and Roness H. Follicle "burn out'': a novel mechanism of chemotherapy induced ovarian damage Fertil. Steril 94 2010 S10
39. Morgan S., Anderson R.A., Gourley C., Wallace W.H., and Spears N. How do chemotherapeutic agents damage the ovary? Hum. Reprod. Update 18 2012 525 535
40. Morgan S., Lopes F., Gourley C., Anderson R.A., and Spears N. Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin PLoS ONE 8 2013 e70117
41. Morita Y., Perez G.I., Paris F., Miranda S.R., Ehleiter D., Haimovitz-Friedman A., Fuks Z., Xie Z., Reed J.C., Schuchman E.H., Kolesnick R.N., and Tilly J.L. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy Nat. Med 6 2000 1109 1114
42. Myers M., Britt K.L., Wreford N.G., Ebling F.J., and Kerr J.B. Methods for quantifying follicular numbers within the mouse ovary Reproduction 127 2004 569 580
43. Oktem O., and Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function Cancer 110 2007 2222 2229
44. Oktem O., and Oktay K. Sphingosine-1-phosphate enhances human primordial follicle survival and blocks ovarian apoptosis in vitro Fertil. Steril 88 2007 S270
45. Oktem O., and Urman B. Options of fertility preservation in female cancer patients Obstet. Gynecol. Surv 65 2010 531 542
46. Paris F., Perez G.I., Fuks Z., Haimovitz-Friedman A., Nguyen H., Bose M., Ilagan A., Hunt P.A., Morgan W.F., Tilly J.L., and Kolesnick R. Sphingosine 1-phosphate preserves fertility in irradiated female mice without propagating genomic damage in offspring Nat. Med 8 2002 901 902
47. Park M.R., Choi Y.J., Kwon D.N., Park C., Bui H.T., Gurunathan S., Cho S.G., Song H., Seo H.G., Min G., and Kim J.H. Intraovarian transplantation of primordial follicles fails to rescue chemotherapy injured ovaries Sci. Rep 3 2013 1384
48. Payne S.G., Milstien S., and Spiegel S. Sphingosine-1-phosphate: dual messenger functions FEBS Lett 531 2002 54 57
49. Perez G.I., Knudson C.M., Leykin L., Korsmeyer S.J., and Tilly J.L. Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction Nat. Med 3 1997 1228 1232
50. Perry D.K. Ceramide and apoptosis Biochem. Soc. Trans 27 1999 399 404
51. Poljicanin A., Vukusic Pusic T., Vukojevic K., Caric A., Vilovic K., Tomic S., Soljic V., and Saraga-Babic M. The expression patterns of pro-apoptotic and anti-apoptotic factors in human fetal and adult ovary Acta Histochem 115 2013 533 540
52. Qi X., Okamoto Y., Murakawa T., Wang F., Oyama O., Ohkawa R., Yoshioka K., Du W., Sugimoto N., Yatomi Y., Takuwa N., and Takuwa Y. Sustained delivery of sphingosine-1-phosphate using poly(lactic-co-glycolic acid)-based microparticles stimulates Akt/ERK-eNOS mediated angiogenesis and vascular maturation restoring blood flow in ischemic limbs of mice Eur. J. Pharmacol 634 2010 121 131
53. Rodrigues P., Limback D., McGinnis L.K., Plancha C.E., and Albertini D.F. Multiple mechanisms of germ cell loss in the perinatal mouse ovary Reproduction 137 2009 709 720
54. Sadeu J.C., Adriaenssens T., and Smitz J. Expression of growth differentiation factor 9, bone morphogenetic protein 15, and anti-Müllerian hormone in cultured mouse primary follicles Reproduction 136 2008 195 203
55. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis Mol. Cell 9 2002 459 470
56. Sonmezer M., and Oktay K. Fertility preservation in female patients Hum. Reprod. Update 10 2004 251 266
57. Spiegel S., and Kolesnick R. Sphingosine 1-phosphate as a therapeutic agent Leukemia 16 2002 1596 1602
58. Sredni B., Albeck M., Tichler T., Shani A., Shapira J., Bruderman I., Catane R., Kaufman B., and Kalechman Y. Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide J. Clin. Oncol 13 1995 2342 2353
59. Sun X., Dongol S., Jiang J., and Kong B. Protection of ovarian function by GnRH agonists during chemotherapy: a meta-analysis Int. J. Oncol 44 2014 1335 1340
60. Tan S.J., Yeh Y.C., Shang W.J., Wu G.J., Liu J.Y., and Chen C.H. Protective effect of a gonadotropin-releasing hormone analogue on chemotherapeutic agent-induced ovarian gonadotoxicity: a mouse model Eur. J. Obstet. Gynecol. Reprod. Biol 149 2010 182 185
61. Treuting P.M., and Dintzis S.M. Comparative Anatomy And Histology: A Mouse and Human Atlas first ed. 2011 Elsevier Science Atlanta, GA
62. Van Disseldorp J., Lambalk C.B., Kwee J., Looman C.W., Eijkemans M.J., Fauser B.C., and Broekmans F.J. Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts Hum. Reprod 25 2010 221 227
63. Yang B., Shi W., Yang J., Liu H., Zhao H., Li X., and Jiao S. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials Breast 22 2013 150 157
64. Zhang Y., Xiao Z., Wang Y., Luo S., Li X., and Li S. Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients PLoS ONE 8 2013 e80444